Disease Markers / 2018 / Article / Tab 1

Review Article

Clinicopathological and Prognostic Significance of Cancer Antigen 15-3 and Carcinoembryonic Antigen in Breast Cancer: A Meta-Analysis including 12,993 Patients

Table 1

Main characteristics of all the studies included in the meta-analysis.

StudyYearStudy regionStudy continentTumor typeSample sizeFollow-up time mean (months)Patients average age (years)Serum sample collected timeStageCA15-3 cut-off value (U/ml)OutcomeCEA cut-off value (ng/ml)OutcomeWhether had association of clinicopathological characteristics with CA15-3 or CEANOS score

Albuquerque1995UKEuropeMetastatic breast cancers85N60.52PretreatmentM40OS4OSNo6
Berruti1994ItalyEuropeAdvanced breast cancer1153556At first recurrence of disease before the start of any endocrine or cytotoxic therapyM30OSNNNo5
Canizares2001SpainEuropePrimary early breast cancer3647256PretreatmentI, II, III40DFS, OS6DFS, OSNo7
Chen2015ChinaAsiaBreast cancer with positive lymph nodes2203649.0PretreatmentII, III, IV28OSNNNo7
Dai2016ChinaAsiaTriple-negative breast cancer24712046.8PretreatmentI–IV21.8DFS, OS6.0DFS, OSYes7
Darlix2016FranceEuropeMetastatic breast cancers25040.858.4Not pretreatmentM30OSNNNo6
Di Gioia2015GermanyEuropeEarly-stage breast cancer24141.557PretreatmentI, II, III24DFS, CSSNNYes7
Duffy2004UKEuropeBreast cancer60075.24NPretreatmentNot clear30OSNNYes7
Elfagieh2012LibyaAfrica29 had locoregional breast cancer and 21 advanced breast cancer5028NNot clearI–IV35.57OS8.82OSYes6
Giovanella2002ItalyEuropePrimary breast cancer2122653.6PretreatmentI–IV30OS5OSNo7
Hewala2013EgyptAfricaStages II and III breast cancer1005048.36PretreatmentII, IIIN4.88DFSNo8
James2003UKEuropeBone metastasis breast cancer213NNAfter metastasisM35OS10OSNo7
Kacan2016TurkeyEuropeEarly-stage breast cancer4485051PretreatmentI, II, III31.3DFS, OS5DFS, OSNo8
Kumpulainen2002FinlandEuropePrimary breast cancer272124.854In most patients, CA15-3 was assessed pre-first treatment; in the minority, by 4 weeks after the operation0–IV30OSNNYes7
Lee2013KoreaAsiaMetastatic breast cancers34918At recurrenceM20.11OS3.88OSYes6
Loprinzi1986South AfricaAfricaMetastatic breast cancers97NNAfter recurrenceMNN5OSYes6
Martin2006SpainEuropePrimary early breast cancer8184359PretreatmentI, II, III30DFSNNYes7
Molina1998SpainEuropePrimary breast cancer413NNPretreatmentI–IV35DFS5.0DFSNo5
Molina2010SpainEuropePrimary breast cancer2062NNPretreatmentI–IV30DFS, OS5DFS, OSYes8
Nakamura2017JapanAsiaPrimary breast cancer20893.655.3Not clear0–IV27OS5OSNo7
Nan2017ChinaAsiaPrimary breast cancer462760PretreatmentNot clearNN2.885OSNo5
Nieder2015NorwayEuropeBreast cancer with brain metastases1413.8Before recurrenceM77OSNNNo5
Nishimiya2014JapanAsiaPrimary breast cancer24712051.7PretreatmentI, II, III28DFS, OS2.5DFS, OSNo8
Nisman2013IsraelAsiaPrimary early breast cancer15976NPretreatmentI, II, III30.0DFSNNYes6
Park2008KoreaAsiaEarly-stage breast cancer74037.247PretreatmentI, II, III20.11DFS, OS3.88DFS, OSYes8
Pierga2012FranceEuropeMetastatic breast cancers8414.957After recurrenceMNNNPFSNo6
Rasmy2016EgyptAfricaEarly-stage breast cancer28033.1849PretreatmentI, II, III25DFS, OSNNYes7
Richard1988USAAmericaStage II and III breast cancer52972NPretreatmentII, IIINN20DFS, OSYes8
Shao2015ChinaAsiaEarly-stage breast cancer432N50PretreatmentI, II, III25DFS, OS5.0DFS, OSYes8
Shering1998IrelandEuropeOperable breast cancer36839.3656PretreatmentI, II, III30DFS, OSNNNo7
Turanli2010TurkeyEuropeIsolated bone metastasis breast cancer1293851After bone metastasisM30PFS, OSNNYes7
Uehara2008JapanAsiaPrimary breast cancer1663NNPretreatmentI–IV28DFS, OS5.0DFS, OSNo7
Velaiutham2008MalaysiaAsiaPrimary breast cancer322NNPretreatmentI–IV50OSNNNo5
Wang2014ChinaAsiaBreast cancer86NNNot clearNot clear25.00OS3.40OSNo5
Wu2014ChinaAsiaEarly-stage breast cancer47049.948PretreatmentI, II, III25DFS, OS5.0DFS, OSYes7
Zhao2011ChinaAsiaStage IV breast cancer with bone metastases6031.448.5PretreatmentM25PFS10PFSNo8

OS: overall survival; PFS: progress-free survival; DFS: disease-free survival; M: metastasis; N: not available; NOS: Newcastle–Ottawa Scale.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.